Druck Icon

Eckert & Ziegler: Positive start to the 2012 financial year

Berlin, May 03, 2012. The Eckert & Ziegler Group (ISIN DE0005659700), a specialist for isotope applications in medicine, science and industry continued its successful performance in the first three months of 2012. As compared to the first quarter of 2011, sales revenues rose by EUR 1.0 million (+4%) to EUR 29.2 million. Profits after taxes and minority interests were roughly the same as during the last four quarters, reaching EUR 2.5 million or EUR 0.47 per share.

The Isotope Products segment accounts for the greatest share of total results. Here sales revenues generated from external customers declined slightly by 1% to EUR 14.0 million. Compared to the same quarter last year, there were slight cost increases, so that EBIT fell by 4% from EUR 4.7 million to EUR 4.5 million. This effect was offset by lower interest payments and taxes, so that the segment’s earnings before minority interests remained constant at EUR 3.1 million.

The Environmental Services segment showed the strongest growth. Sales revenues from external customers surged by 44% to EUR 1.7 million. The segment generated EBIT of EUR 0.1 million.

The 8% growth in sales revenues in the Radiation Therapy segment (to EUR 7.2 million) was also gratifying. Here the new generation of afterloaders accounted for a rise in sales revenues, while the implants to combat prostate cancer continued to deliver constant sales revenues. Extensive information on the Radiation Therapy segment can be found in the Eckert & Ziegler BEBIG s.a. quarterly report, which appears simultaneously with this report (www.bebig.eu).

Growth slowed in the Radiopharma segment. Thanks to the Bioscan acquisition in mid-2011, sales revenues grew by 2% in the segment to EUR 6.4 million. In comparison to the unusually strong first quarter of 2011, EBIT fell by 67% to EUR 0.5 million.

To read the full report please click here: http://www.ezag.com/fileadmin/ezag/user-uploads/pdf/financial-reports/englisch/euz112e.pdf

The board of directors and supervisory board will suggest a dividend of 0.60 per share at the Annual General Meeting on 24th May 2012.

Sales of approx. EUR 117 million and a result after tax and minority interests of approx. EUR 10 million are expected for the fiscal year 2012.

With around 590 employees the Eckert & Ziegler Group belongs to the largest providers of isotope components for radiotherapy and nuclear medicine worldwide.

If you have any questions please contact:

Eckert & Ziegler AG, Karolin Riehle, Investor Relations, Robert-Rössle-Str. 10, 13125 Berlin

Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@dont-want-spam.ezag.de, www.ezag.de